Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you suffered purchased or acquired securities in Altimmune between August 10, 2023 and ...

We expect investors to focus on Altimmune’s ALT progress in the studies evaluating its lead pipeline candidate, pemvidutide, when it reports second-quarter 2025 results. Since ALT lacks a marketed ...

Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors ...

The Allegations: Rosen Law Firm is Investigating the Allegations that Altimmune, Inc. (NASDAQ: ALT) Misled Investors Regarding its Business Operations.

Altimmune, Inc. (NASDAQ:ALT) reported a cash position of $182 million in Q1 2024, a 9.83% increase in cash over the same quarter the previous year, and a $24.3 million net loss.

Altimmune Inc. (NASDAQ: ALT) is completing a Phase 2 clinical trial of pemvidutide, an anti-obesity drug that appears to be able to bring important benefits to weight loss.

Altimmune, a clinical-stage biopharmaceutical company, is making strides in its peptide research, developing therapeutic agents with the potential to treat serious health conditions like liver ...

Altimmune (ALT) stock sold off after the company announced its plan to scrap its COVID19 vaccine programs, and ALT is currently trading at an enterprise value of around US$120M.

Altimmune Inc. ALT shares rallied more than 40% in the extended session Thursday after the clinical-stage biopharma company said 391 people enrolled in a trial of its obesity drug pemvidutide lost ...

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is ...

Altimmune's stock has tumbled 21.1% over the past three months through Monday, while the iShares Nasdaq Biotechnology ETF has lost 4.3% and the S&P 500 has gained 3.4%.

Altimmune, which merged with publicly held PharmAthene Inc. in May, is raising $14.7 million through a preferred stock offering.